Skip to content

Study · Other design · n = 14,752 · 2018

2 results

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD and 8 more

Show all authors

Maggioni AP, Öhman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF

Journal of the American Heart Association1 Oct 2018Cited by 26 (Europe PMC)

PMID30371301 (opens in a new tab)PMCIDPMC6404902 (opens in a new tab)DOI10.1161/jaha.118.009304 (opens in a new tab)PepBankPUB-30371301
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanOther designEfficacy outcome

    In adults with type 2 diabetes, the exenatide treatment effect on MACE did not interact with baseline risk profile.

    In plain wordsIn adults with type 2 diabetes, exenatide's effect on major cardiovascular events did not differ across baseline risk profiles.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMACE treatment-effect interaction with baseline risk
    Study

    n = 14,752

    Comparator
    baseline risk profiles
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No interaction was observed between treatment effect and risk profile for either end point (both interactions, P>0.1).
    2 context sentences
    Summary · context
    Methods and Results In the EXSCEL population, we created risk scores for MACEs and all-cause mortality using step-wise selection of baseline characteristics.
    Summary · context
    A risk score was calculated for each patient, and a time-to-event model for each end point was developed including the risk score, treatment assignment, and risk-treatment interaction.
  2. 02HumanOther designEfficacy outcome

    In adults with type 2 diabetes, the exenatide treatment effect on all-cause mortality did not interact with baseline risk profile.

    In plain wordsIn adults with type 2 diabetes, exenatide's effect on death did not differ across baseline risk profiles.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMortality treatment-effect interaction with baseline risk
    Study

    n = 14,752

    Comparator
    baseline risk profiles
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No interaction was observed between treatment effect and risk profile for either end point (both interactions, P>0.1).
    2 context sentences
    Summary · context
    Methods and Results In the EXSCEL population, we created risk scores for MACEs and all-cause mortality using step-wise selection of baseline characteristics.
    Summary · context
    A risk score was calculated for each patient, and a time-to-event model for each end point was developed including the risk score, treatment assignment, and risk-treatment interaction.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

AstraZenecan = 14,75218 Jun 2010 to 24 Apr 2017

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 8 Aug 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.